A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Kathryn R. Wagner(Kennedy Krieger Institute), Jerry R. Mendell(Nationwide Children's Hospital), Cristina Csimma(Women's Health Research Institute), Kathleen N. Meyers(Hospital for Special Surgery), Volker Straub(Newcastle upon Tyne Hospitals NHS Foundation Trust), Stephanie A. Parsons, Diana M. Escolar(Children's National), Alan Pestronk(Washington University in St. Louis), Kevin M. Flanigan(Nationwide Children's Hospital), Robert H. Allen(Columbia University Irving Medical Center), Gil I. Wolfe(University at Buffalo, State University of New York), Paul Juneau(National Institutes of Health), Michelle Eagle(Newcastle University), John M. Wozney(Unknown), Tracey Araujo(Women's Health Research Institute), Anthony A. Amato(Brigham and Women's Hospital), Julaine Florence, Shree Pandya(University of Rochester Medical Center), K. Bushby(Newcastle University), Richard J. Barohn(University of Missouri Health System), Wendy King(The Ohio State University), Rabi Tawil(University of Rochester Medical Center), James L. Fleckenstein(University of Oklahoma), Edward R. LaVallie(Boston University)
Cited by 466
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Improving genetic diagnosis in Mendelian disease with transcriptome sequencing
|Science Translational Medicine|2017|809